DÄ internationalArchiveReferences
References

Review article

The Therapeutic Potential of Cannabis and Cannabinoids

Dtsch Arztebl Int 2012; 109(29-30): 495-501. DOI: 10.3238/arztebl.2012.0495

Grotenhermen, F; Müller-Vahl, K

1. Grotenhermen F: Cannabis und Cannabinoide. Pharmakologie, Toxikologie und therapeutisches Potential. 2nd edition. Göttingen: Hans Huber 2004.
2. Lambert DM: Cannabinoids in Nature and Medicine. Weinheim: Wiley-Vch. Verlag GmbH & Co. KGaA 2009.
3. Mechoulam R: Cannabinoids as Therapeutics. Basel: Birkhäuser Verlag 2005. CrossRef
4. Radbruch L, Nauck F: Cannabinoide in der Medizin. Bremen: Unimed 2006.
5. Guy G, Whittle BA, Robson PJ: Medicinal Uses of Cannabis and Cannabinoids. London: Pharmaceutical Press 2004.
6. Stellungnahme der Bundes­ärzte­kammer, der Kassenärztlichen Bundesvereinigung und der Arznei­mittel­kommission der deutschen Ärzteschaft zu den Anträgen der Fraktion Bündnis 90/Die Grünen „Medizinische Verwendung von Cannabis erleichtern“ vom 27. 11. 2007 und der Fraktion Die Linke „Cannabis zur medizinischen Behandlung freigeben“ vom 25.06.2008. Ausschussdrucksache 16(14)0420(9). Deutscher Bundestag, Ausschuss für Gesundheit.
7. Fankhauser M: Cannabis in der westlichen Medizin. In: Grotenhermen F (ed.): Cannabis und Cannabinoide. Pharmakologie, Toxikologie und therapeutisches Potential. 2nd edition. Göttingen: Hans Huber 2004; 57–71.
8. Gaoni Y, Mechoulam R: Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86: 1646–7. CrossRef
9. Pertwee RG: Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009; 156: 397–411. CrossRef MEDLINE PubMed Central
10. Grotenhermen F: Cannabinoids. Curr Drug Targets CNS Neurol Disord 2005; 4: 507–30. CrossRef MEDLINE
11. ElSohly M: Chemische Bestandteile von Cannabis. In: Grotenhermen F (ed.): Cannabis und Cannabinoide. Pharmakologie, Toxikologie und therapeutisches Potential. 2nd edition. Göttingen: Hans Huber 2004; 45–55.
12.Pertwee RG, Howlett AC, Abood ME, et al.: Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 2010; 62: 588–631. CrossRef MEDLINE PubMed Central
13.O’Sullivan SE, Kendall DA: Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology 2010; 215: 611–6. CrossRef MEDLINE
14. Grotenhermen F: The toxicology of cannabis and cannabis prohibition. Chem Biodivers 2007; 4: 1744–69. CrossRef
15.Grant I, Gonzalez R, Carey CL, Natarajan L, Wolfson T: Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc 2003; 9: 679–89. CrossRef MEDLINE
16. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL: Dose-related neurocognitive effects of marijuana use. Neurology 2002; 59: 1337–43. CrossRef MEDLINE
17. Moore TH, Zammit S, Lingford-Hughes A, et al.: Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319–28. CrossRef MEDLINE
18. Hézode C, Zafrani ES, Roudot-Thoraval F, et al.: Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 2008; 134: 432–9. CrossRef MEDLINE
19. Vandrey RG, Budney AJ, Hughes JR, Liguori A: A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances. Drug Alcohol Depend 2008; 92: 48–54. CrossRef MEDLINE PubMed Central
20. Beal JE, Olson R, Lefkowitz L, et al.: Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997; 14: 7–14. CrossRef MEDLINE
21. Kosel BW, Aweeka FT, Benowitz NL, et al.: The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 2002; 16: 543–50. CrossRef MEDLINE
22. Engels FK, de Jong FA, Sparreboom A, et al.: Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. Oncologist 2007; 12: 291–300. CrossRef MEDLINE
23. Hollister LE: Interactions of marihuana and 9-THC with other drugs. In: Nahas G, Sutin KM, Harvey DJ, Agurell S (eds.): Marihuana and Medicine. Totowa, NJ: Humana Press 1999: 273–7.
24. IACM: Studies and case reports. Available at: www.cannabis-med.org/
english/studies.htm.
e1. Killestein J, Hoogervorst EL, Reif M, et al.: Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58: 1404–7. MEDLINE
e2. Zajicek J, Fox P, Sanders H, et al.: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362: 1517–26. MEDLINE
e3. Centonze D, Mori F, Koch G, et al.: Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis. Neurol Sci 2009; 30: 531–4. MEDLINE
e4. Petro DJ, Ellenberger C: Treatment of human spasticity with 9-tetrahydrocannabinol. J Clin Pharmacol 1981; (Suppl 21): 413–6. MEDLINE
e5.Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW: 9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Substance Abuse 1987; 7: 39–50. MEDLINE
e6. Zajicek JP, Sanders HP, Wright DE, et al.: Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005; 76: 1664–9. MEDLINE
e7. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al.: Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Multiple Sclerosis 2004; 10: 417–24. MEDLINE
e8. Wade DT, Makela P, Robson P, House H, Bateman C: Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004; 10: 434–41. CrossRef MEDLINE
e9. Wade DT, Makela PM, House H, Bateman C, Robson P: Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006; 12: 639–45. CrossRef MEDLINE
e10. Collin C, Davies P, Mutiboko IK, Ratcliffe S, for the Sativex Spasticity in MS Study Group: Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurology 2007; 14: 290–6. MEDLINE
e11. Conte A, Bettolo CM, Onesti E, et al.: Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis. Eur J Pain 2009; 13: 472–7. MEDLINE
e12. Novotna A, Mares J, Ratcliffe S, et al.: A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011; 18: 1122–31. MEDLINE
e13. Hanigan WC, Destree R, Truong XT: The effect of D9-THC on human spasticity. Clin Pharmacol Ther 1986; 39: 198.
e14. Hagenbach U, Luz S, Ghafoor N, et al.: The treatment of spasticity with delta-9-tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord 2007; 45: 551–62. MEDLINE
e15. Pooyania S, Ethans K, Szturm T, Casey A, Perry D: A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury. Arch Phys Med Rehabil 2010; 91: 703–7. CrossRef MEDLINE
e16. Artim R, DiBella N: Tetrahydrocannabinol (THC) plus prochlorperazine (PCZ) for refractory nausea and vomiting (N/V). Proc Am Soc Clin Oncol 1983; 2: 84.
e17. Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I: Delta-9-tetrahydrocannabinol as an antiemetics in cancer patients receiving high-dose methotrexate. Ann Int Med 1979; 91: 819–24. MEDLINE
e18. Chang AE, Shiling DJ, Stillman RC, et al.: A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 1981; 47: 1746–51. MEDLINE
e19. Colls BM, Ferry DG, Gray AJ, Harvey VJ, McQueen EG: The antiemetic activity of tetrahydrocanabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. N Z Med J 1980; 91: 449–51. MEDLINE
e20. Ekert H, Waters KD, Jurk KH, Mobilia J, Loughnan P: Amelioration of cancer chemotherapy-induced nausea and vomiting by 9-tetrahydrocannabinol. Med J Aust 1979; 2: 657–9. MEDLINE
e21. Frytak S, Moertel CG, O’Fallon JR, Rubin J, Creagan ET, O’Connnell MJ: Delta-9-tetrahydrocannabinol as an antiemetics for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Int Med 1979; 91: 825–30. MEDLINE
e22. Gralla RJ, Tyson LB, Bordin LA, Clark RA, Kelsen DP, Kris MG: Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. Can Treat Rep 1984; 68: 163–72. MEDLINE
e23. Kluin-Nelemans JC, Nelemans FA, Meuwissen OJATh, Maes RAA: 9-tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancer chemotherapy; a double-blind cross-over trial against placebo. Vet Hum Toxicol 1979; 21: 338–40. MEDLINE
e24. Lane M, Vogel CL, Ferguson J, Krasnow S, Saiers JL, Hamm J: Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Sym Manag 1991; 6: 352–9. MEDLINE
e25. Levitt M, Faiman C, Hawks R, Wilson A: Randomized double blind comparison of delta-9-tetrahydroicannabinol (THC) and marijuana as chemotherapy antiemetics. Proc Am Soc Clin Oncol 1984; 3: 91.
e26. Levitt M, Wilson A, Bowman D, Faiman C, Kemel S, Krepart G: Dose vs response of tetrahydroannabinol (THC) vs prochlorperazine as chemotherapy antiemetics. Proc Am Soc Clin Oncol 1981; 22: 422.
e27. McCabe M, Smith FP, Goldberg D, Macdonald J, Woolley PV, Warren R: Efficacy of tetrahydrocannabinol in patients refractory to standard anti-emetic therapy. Invest New Drugs 1988; 6: 243–6. MEDLINE
e28. Neidhart JA, Gagen MM, Wilson HE, Young DC: Comparative trial of the antiemetic effects of THC and haloperidol. Int J Clin Pharmacol Res 1981; 21: 38–42. MEDLINE
e29. Orr LE, McKernan JF, Bloome B: Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Int Med 1980; 140: 1431–33. CrossRef MEDLINE
e30. Sallan SE, Cronin C, Zelen M, Zinberg NE: Antiemetics in patients receiving chemotherapy for cancer. A randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med 1980; 302: 135–8. CrossRef MEDLINE
e31. Sallan SE, Zinberg NE, Frei E: Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 1975; 293: 795–7. CrossRef MEDLINE
e32. Ungerleider JT, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K: Cannabis and cancer chemotherapy. A comparison of oral delta-9-THC and prochlorperazine. Cancer 1982; 50: 636–45. MEDLINE
e33. Ungerleider JT, Sarna G, Fairbanks LA, Goodnight J, Andrysiak T, Jamison K: THC or compazine for the cancer chemotherapy patient – the UCLA study. Part II: patient drug preference. Am J Clin Oncol 1985; 8: 142–7. MEDLINE
e34. Meiri E, Jhangiani H, Vredenburgh JJ, et al.: Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 2007; 23: 533–43. MEDLINE
e35. Duran M, Pérez E, Abanades S, et al.: Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol 2010; 70: 656–63. MEDLINE
e36. Ahmedzai S, Carlyle DL, Clader IT, Moran F: Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer 1983; 48: 657–63. MEDLINE PubMed Central
e37. Chan HS, Correia JA, MacLeod SM: Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 1987; 79: 946–52. MEDLINE
e38. Crawford SM, Buckman R: Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study. Med Oncol Tumour Pharmacother 1986; 3: 39–42. MEDLINE
e39. Cunningham D, Bradley CJ, Forrest GJ, et al.: A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Can Clin Oncol 1988; 24: 685–9. MEDLINE
e40. Dalzell AM, Bartlett H, Lilleyman JS: Nabilone: An alternative antiemetic for cancer chemotherapy. Arch Dis Child 1986; 61: 502–5. MEDLINE PubMed Central
e41. Einhorn LH, Nagy C, Furnas B, Williams SD: Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol 1981; 21(8–9 Suppl): 64–9. MEDLINE
e42. George M, Pejovic MH, Thuaire M, Kramar A, Wolff JP: Randomized comparative trial of a new anti-emetic: nabilone, in cancer patients treated with cisplatin. Biomed Pharmacother 1983; 37: 24–7. MEDLINE
e43. Herman TS, Einhorn LH, Jones SE, et al.: Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 1979; 300: 1295–7. MEDLINE
e44. Johansson R, Kilkku P, Groenroos M: A double-blind, controlled trial of nabilone vs prochlorperazine for refractory emesis induced by cancer chemotherapy. Can Treat Rev 1982; 9: 25–33. CrossRef MEDLINE
e45. Jones SE, Durant JR, Greco FA, Robertone A: A multi-institutional phase III study of nabilone vs placebo in chemotherapy-induced nausea and vomiting. Can Treat Rev 1982; 9: 45–8. CrossRef MEDLINE
e46. Levitt M: Nabilone vs placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Can Treat Rev 1982; 9(suppl B): 49–53. CrossRef MEDLINE
e47. Nagy CM, Furnas BE, Einhorn LH, Bond WH: Nabilone: antiemetic crossover study in cancer chemotherapy patients. Proc Am Soc Can Res 1978; 19: 30.
e48. Niederle N, Schutte J, Schmidt CG: Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Klin Wochenschr 1986; 64: 362–5. CrossRef MEDLINE
e49. Niiranen Aila, Mattson K: A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol 1985; 8: 336–40. CrossRef MEDLINE
e50. Pomeroy M, Fennelly JJ, Towers M: Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Can Chemother Pharmacol 1986; 17: 285–8. MEDLINE
e51. Steele N, Gralla RJ, Braun Jr DW, Young CW: Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Can Treat Rep 1980; 64: 219–24. MEDLINE
e52. Wada JK, Bogdon DL, Gunnell JC, Hum GJ, Gota CH, Rieth TE: Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy. Cancer Treatment Rev 1982; 9(Suppl B): 39–44. MEDLINE
e53. Citron ML, Herman TS, Vreeland F, Krasnow SH, Fossieck BE Jr: Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting. Cancer Treat Rep 1985; 69: 109–12. MEDLINE
e54. Higi M, Niederle N, Bremer K, Schmitt G, Schmidt CG, Seeber S: Levonantradol bei der Behandlung von zytostatika-bedingter Übelkeit und Erbrechen. Dtsch Med Wochenschr 1982; 107: 1232–4. MEDLINE
e55. Hutcheon AW, Palmer JB, Soukop M, et al.: A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with ychlorpromazine in patients receiving their first cytotoxic chemotherapy. Eur J Can Clin Oncol 1983; 19: 1087–90. MEDLINE
e56. Stambaugh Jr JE, McAdams J, Vreeland F: Dose ranging evaluation of the antiemetic efficacy and toxicity of intramuscular levonantradol in cancer subjects with chemotherapy-induced emesis. Int J Clin Pharmacol Res 1984; 24: 480–5. MEDLINE
e57. American Society of Clinical Oncology, Kris MG, Hesketh PJ, et al.: American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 2006; 24: 2932–47. MEDLINE
e58. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Antiemesis, V.3.2008. Available at: www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf.
e59. Struwe M, Kaempfer SH, Geiger CJ, et al.: Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 1993; 27: 827–31. MEDLINE
e60. Beal JE, Olson R, Laubenstein L, et al.: Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Sympt Manag 1995; 10: 89–97. MEDLINE
e61. Timpone JG, Wright DJ, Li N, et al.: The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Res Hum Retroviruses 1997; 13: 305–15. MEDLINE
e62. Bedi G, Foltin RW, Gunderson EW, et al.: Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study. Psychopharmacology 2010; 212: 675–86. MEDLINE
e63. Abrams DI, Hilton JF, Leiser RJ, et al.: Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med 2003; 139: 258–66. MEDLINE
e64.Haney M, Rabkin J, Gunderson E, Foltin RW: Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology 2005; 181: 170–8. MEDLINE
e65.Haney M, Gunderson EW, Rabkin J, et al.: Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. J Acquir Immune Defic Syndr 2007; 45: 545–54. MEDLINE
e66. Jatoi A, Windschitl HE, Loprinzi CL, et al.: Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002; 20: 567–73. MEDLINE
e67. Regelson W, Butler JR, Schulz J, et al.: Delta-9-tetrahydrocannabinol as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. In: Braude MC, Szara S (eds.): Pharmacology of marihuana. Vol 2. New York: Raven Press 1976; 763–76.
e68. Brisbois TD, de Kock IH, Watanabe SM, et al.: Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol 2011; 22: 2086–93. MEDLINE
e69. Cannabis-In-Cachexia-Study-Group, Strasser F, Luftner D, et al.: Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 2006; 24: 3394–400. MEDLINE
e70. Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ: Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 1997; 12: 913–9. MEDLINE
e71. Svendsen KB, Jensen TS, Bach FW: Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; 329: 253. CrossRef MEDLINE PubMed Central
e72. Rintala DH, Fiess RN, Tan G, Holmes SA, Bruel BM: Effect of dronabinol on central neuropathic pain after spinal cord injury: a pilot study. Am J Phys Med Rehabil 2010; 89: 840–8. CrossRef MEDLINE
e73. Wade DT, Robson P, House H, Makela P, Aram J: A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17: 18–26. MEDLINE
e74. Berman JS, Symonds C, Birch R: Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 2004; 112: 299–306. CrossRef MEDLINE
e75. Wissel J, Haydn T, Müller J, et al.: Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial. J Neurol 2006; 253: 1337–41 MEDLINE
e76. Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D: Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ 2008; 336: 199–201 CrossRef MEDLINE PubMed Central
e77. Rog DJ, Nurmikko TJ, Friede T, Young CA: Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65: 812–9 CrossRef MEDLINE
e78. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D: Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 2007; 133: 210–20 MEDLINE
e79. Selvarajah D, Gandhi R, Emery CJ, Tesfaye S: Randomised Placebo Controlled Double Blind Clinical Trial of Cannabis Based Medicinal Product (Sativex) in Painful Diabetic Neuropathy: Depression is a Major Confounding Factor. Diabetes Care 2010; 33: 128–30 CrossRef MEDLINE PubMed Central
e80. Abrams DI, Jay CA, Shade SB, et al.: Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. Neurology 2007; 68: 515–21 MEDLINE
e81. Wilsey B, Marcotte T, Tsodikov A, et al.: A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain 2008; 9: 506–21 MEDLINE
e82. Ellis RJ, Toperoff W, Vaida F, et al.: Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009; 34: 672–80 MEDLINE
e83. Ware MA, Wang T, Shapiro S, et al.: Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010; 182: 694–701 MEDLINE
e84. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U: Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 2003; 290: 1757–6 MEDLINE
e85. Noyes R, Brunk SF, Baram DA, Canter A: Analgesic effects of delta-9-THC. J Clin Pharmacol 1975; 15: 139–43 MEDLINE
e86. Noyes R, Brunk ST, Avery DH, Canter A: The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975; 18: 84–9 MEDLINE
e87. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT: Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD Extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 2010; 39: 167–79. MEDLINE
e88. Staquet M, Gantt C, Machin D: Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin Pharmacol Ther 1978; 23: 397–401 MEDLINE
e89. Jochimsen PR, Lawton RL, VerSteeg K, Noyes Jr R: Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clin Pharmacol Ther 1978; 24: 223–7 MEDLINE
e90. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS: Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 2006; 45: 50–2 CrossRef MEDLINE
e91. Skrabek RQ, Galimova L, Ethans K, Perry D: Nabilone for the treatment of pain in fibromyalgia. J Pain 2008; 9: 164–73 MEDLINE
e92. Ware MA, Fitzcharles MA, Joseph L, Shir Y: The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 2010; 110: 604–10 CrossRef MEDLINE
e93. Narang S, Gibson D, Wasan AD, et al.: Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain 2008; 9: 254–64 MEDLINE
e94. Notcutt W, Price M, Miller R, et al.: Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ’N of 1’ studies. Anaesthesia 2004; 59: 440–52 MEDLINE
e95. Ware MA, Ducruet T, Robinson AR: Evaluation of herbal cannabis characteristics by medical users: a randomized trial. Harm Reduct J 2006; 3: 32 CrossRef MEDLINE PubMed Central
e96. Pinsger M, Schimetta W, Volc D, Hiermann E, Riederer F, Polz W: Nutzen einer Add-On-Therapie mit dem synthetischen Cannabinomimetikum Nabilone bei Patienten mit chronischen Schmerzzuständen – eine randomisierte kontrollierte Studie. Wien Klin Wochenschr 2006; 118: 327–35 MEDLINE
e97. Raft D, Gregg J, Ghia J, Harris L: Effects of intravenous tetrahydrocannabinol on experimental and surgical pain: psychological correlates of the analgesic response. Clin Pharmacol Ther 1977; 21: 26–33 MEDLINE
e98. Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ: Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain 2003; 106: 169–72 MEDLINE
e99. Seeling W, Kneer L, Buchele B, et al.: Delta-9-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative pain. Anaesthesist 2006; 55: 391–400 MEDLINE
e100. Holdcroft A, Maze M, Dore C, Tebbs S, Thompson S: A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology 2006; 104: 1040–6 CrossRef MEDLINE
e101. Beaulieu P: Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth 2006; 53: 769–75 CrossRef MEDLINE
e102. Jain AK, Ryan JR, McMahon FG, Smith G: Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol 1981; 21(suppl 8–9): 320–6 MEDLINE
e103. Kantor TG, Hopper M: A study of levonantradol, a cannabinol derivative, for analgesia in post operative pain. Pain 1981; (suppl): S37.
e104. Ostenfeld T, Price J, Albanese M, et al.: A randomized, controlled study to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in patients with acute pain following third molar tooth extraction. Clin J Pain 2011; 27: 668–76 MEDLINE
e105. Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J: The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct 2006; 17: 636–41 CrossRef MEDLINE
e106. Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ: An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Multiple Sclerosis 2004; 10: 425–33 MEDLINE
e107. Kavia RB, De Ridder D, Constantinescu CS, Stott CG, Fowler CJ: Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler 2010; 16: 1349–59 MEDLINE
e108. Müller-Vahl KR, Schneider U, Koblenz A, et al.: Treatment of Tourette’s syndrome with 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 2002; 35: 57–61 MEDLINE
e109.Müller-Vahl KR, Schneider U, Prevedel H, et al.: 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 2003; 64: 459–65. MEDLINE
e110. Sieradzan KA, Fox SH, Dick J, Brotchie JM: The effects of the cannabinoid receptor agonist nabilone on L-DOPA induced dyskinesia in patients with idiopathic Parkinson’s disease (PD). Movement Disorders 1998; 13(Suppl 2): 29.
e111. Schwarcz G, Karajgi B, McCarthy R: Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia. J Clin Psychopharmacol 2009; 29: 255. CrossRef MEDLINE
e112. Schwarcz G, Karajgi B: Improvement in refractory psychosis with dronabinol: four case reports. J Clin Psychiatry 2010; 71: 1552–3 CrossRef MEDLINE
e113. Jones RT, Benowitz N, Bachman J: Clinical studies of cannabis tolerance and dependence. Ann N Y Acad Sci 1976; 282: 221–39 MEDLINE
e114. Stefanis C: Biological aspects of cannabis use. NIDA Res Monogr 1978; 19: 149–78 MEDLINE
e115. Elsner F, Radbruch L, Sabatowski R: Tetrahydrocannabinol zur Therapie chronischer Schmerzen. Schmerz 2001; 15: 200–4 MEDLINE
e116. Hirvonen J, Goodwin RS, Li CT, et al.: Reversible and regionally selective down regulation of brain cannabinoid CB(1) receptors in chronic daily cannabis smokers. Molecular Psychiatry 2012; 17, 642–49 MEDLINE
e117. Kurzthaler I, Bodner T, Kemmler G, et al.: The effect of nabilone on neuropsychological functions related to driving ability: an extended case series. Hum Psychopharmacol 2005; 20: 291–3. MEDLINE
e118. Brunnauer A, Segmiller FM, Volkamer T, Laux G, Müller N, Dehning S: Cannabinoids improve driving ability in a Tourette’s patient. Psychiatry Res 2011; 190: 382 MEDLINE
e119. Strohbeck-Kuehner P, Skopp G, Mattern R: Fahrtüchtigkeit trotz (wegen) THC. Arch Kriminol 2007; 220: 11–9 MEDLINE